Role of ABCC2 Gene Polymorphism on Deferasirox Hepatic Toxicity in Thalassemia Patients


  • Zahraa Hussain Department of Pharmacology and Toxicology, College of Pharmacy, University of Kerbala, Kerbala, Iraq
  • Amal Umran Mosa Department of Pharmacology and Toxicology, College of Pharmacy, University of Kerbala, Kerbala, Iraq
  • Mohammed Nnaji Atiyeh Karbala Teaching Hospital for Children., Kerbala Health Directorates, Kerbala, Iraq.
  • Ahmed Salih Sahib Department of Pharmacology and Toxicology, College of Pharmacy, University of Kerbala, Kerbala, Iraq.



thalassemia,ABCC2genepolymorphism,deferasorox, hepatotoxicity.


Objectives: To investigate the relationship between ABCC2 gene polymorphism (G>A, rs 8187710) and (C>T, rs 717620) and hepatotoxicity in thalassemia patient treated deferasirox .

Methods: The present work included a cross sectional study, 100 patients suffering iron overload and thalassemia out of 650 patients in (thalassemia center) and 100 healthy patients to compare the parameters of liver function tests of thalassemia patients with healthy group. The allele specific polymerase chain reaction technique (pcr) was used to detect the (G>A, rs 8187710) and (C>T, rs 717620 single nucleotide polymorphism (SNP).

Results : 58 patients with rs 8187710 who are wild (GG) and 32 patients hetero(GA)and 56 patients with rs 717620 who wild (CC) and 31 hetero (CT) are exposed to hepatotoxicity than patients with homo groups

 Conclusion: According to the results of the currents study, the (G>A, rs 8187710) and (C>T, rs 717620) single nucleotide polymorphism (SNP) was associated with hepatotoxicity in patients treated deferasirox.


Joulaei, Hassan et al. 2014. “The Diminishing Trend of β-Thalassemia in Southern Iran from 1997 to 2011: The Impact of Preventive Strategies.” Hemoglobin 38(1): 19–23.

Kim, Daniel et al. 2011. “Rapid Monitoring of Iron‐chelating Therapy in Thalassemia Major by a New Cardiovascular MR Measure: The Reduced Transverse Relaxation Rate.” NMR in Biomedicine 24(7): 771–77.

Persons, Derek A. 2010. “Targeting β-Thalassaemia.” Nature 467(7313): 277–78.

Mobarra, Naser et al. 2016. “A Review on Iron Chelators in Treatment of Iron Overload Syndromes.” International journal of hematology-oncology and stem cell research 10(4): 239.

Poggiali, E., Cassinerio, E., Zanaboni, L. and Cappellini, M.D., 2012. An update on iron chelation therapy. Blood Transfusion, 10(4), p.411.

Bruin, Gerard J M et al. 2008. “Pharmacokinetics, Distribution, Metabolism, and Excretion of Deferasirox and Its Iron Complex in Rats.” Drug metabolism and disposition 36(12): 2523–38.

Haenisch, S et al. 2007. “Influence of Polymorphisms of ABCB1 and ABCC2 on MRNA and Protein Expression in Normal and Cancerous Kidney Cortex.” The pharmacogenomics journal 7(1): 56–65.

Porter, D., & Taher, J. , 2023. (n.d.). 4 TH EDITION (Version 2.0) SSAEMIA

Lee, Ji Won et al. 2013. “Pharmacogenetic Study of Deferasirox, an Iron Chelating Agent.” PLoS One 8(5): e64114.

Braga, Caroline C B et al. 2017. “Deferasirox Associated with Liver Failure and Death in a Sickle Cell Anemia Patient Homozygous for The− 1774delG Polymorphism in the Abcc2 Gene.” Clinical Case Reports 5(8): 1218.

Cao, Kangna et al. 2020. “ABCC2 c.-24 C> T Single-Nucleotide Polymorphism Was Associated with the Pharmacokinetic Variability of Deferasirox in Chinese Subjects.” European Journal of Clinical Pharmacology 76: 51–59.

Marano, M et al. 2016. “Deferasirox-Induced Serious Adverse Reaction in a Pediatric Patient: Pharmacokinetic and Pharmacogenetic Analysis.” European journal of clinical pharmacology 72: 247–48.

Hartung, Thomas. 2009. “Toxicology for the Twenty-First Century.” Nature 460(7252): 208–12.

Vuda, Madhusudanarao, and Ashwin Kamath. 2016. “Drug Induced Mitochondrial Dysfunction: Mechanisms and Adverse Clinical Consequences.” Mitochondrion 31: 63–74.

Díaz-García, Juan Daniel et al. 2014. “Deferasirox Nephrotoxicity—the Knowns and Unknowns.” Nature reviews nephrology 10(10): 574–86.

Bagnasco, SERENA, DAVID Good, ROBERT Balaban, and MAURICE Burg. 1985. “Lactate Production in Isolated Segments of the Rat Nephron.” American Journal of Physiology-Renal Physiology 248(4): F522–26.

Xu, Wenjing, Tomasa Barrientos, and Nancy C Andrews. 2013. “Iron and Copper in Mitochondrial Diseases.” Cell metabolism 17(3): 319–28.

Dixon, Scott J et al. 2012. “Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death.” cell 149(5): 1060–72.

Poli, Giuseppe. 2000. “Pathogenesis of Liver Fibrosis: Role of Oxidative Stress.” Molecular aspects of medicine 21(3): 49–98.

Jensen, Peter D et al. 2003. “Relationship between Hepatocellular Injury and Transfusional Iron Overload Prior to and during Iron Chelation with Desferrioxamine: A Study in Adult Patients with Acquired Anemias.” Blood, The Journal of the American Society of Hematology 101(1): 91–96.




How to Cite

Hussain , Z. ., Mosa , A. U. ., Atiyeh , M. N. ., & Sahib, A. S. . (2024). Role of ABCC2 Gene Polymorphism on Deferasirox Hepatic Toxicity in Thalassemia Patients. Journal of Contemporary Medical Sciences, 10(2).